PATHOGENETIC FOUNDATION OF LOSARTAN TREATMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH ASYMPTOMATIC HYPERURICEMIA
Abstract
In the article the problem of the influence of hyperuricemia on the development and course of cardiovascular disease are presented. Based on several studies it have shown that there is growing evidence about the negative impact of non-traditional risk factors such as hyperuricemia, microalbuminuria and others on the prognosis of cardiovascular diseases, including patients with chronic kidney disease. Based on data from clinical studies have shown that losartan can block the reabsorption of uric acid in the proximal tubules of the kidneys, reducing levels of uric acid in patients with chronic kidney disease, hypertension and asymptomatic hyperuricemia.
Downloads
References
Астахова Н.Ю. Рання діагностика, патогенез і оптимізація лікування уражень нирок у хворих на подагру / Автореф. дис. на здобуття наук.ступіня кандидата мед. наук. Донецьк. - 2005. – 16 С.
Дроздов В.М. Обмен мочевой кислоты у больных с гипертонической болезнью и метаболическим синдромом / Автореф. дис. на соискание науч. степени кандидата мед. наук. Москва - 1999. - 21С.
Тепляков А.Т. Иммуномодулирующие, метаболические и кардиопротективные влияния блокатора АТ1-ангиотензиновых рецепторов лозартана у больных ишемической болезнью сердца с сахарным диабетом 2-го типа / Тепляков А.Т., Маянская С.Д., Болотская Л.А. и др. // Терапевт. арх. - 2009. - Т.81. - № 3. - С. 62-69.
Alderman M.H. Serum Uric Acid As a Cardiovascular Risk Factor for Heart Disease / M.H. Alderman // Current Hypertension Reports. – 2001. – Vol. 3. – P. 1841-1889.
Alderman M.H. Serum uric acid and cardiovascular events in successfully treated hypertensive patients / M.H. Alderman, H. Cohen, S. Madhavan, S. Kivlighn
// Hypertension. – 1999. – Vol. 34. – P. 1441-1450.
Argani H. Effects of losartan and enalapril on high-sensitivity C-reactive protein and total antioxidant in renal transplant recipients with renin-angiotensin system polymorphisms / Argani H., Ghorbanihaghjo A., Aghaeishahsavari M. et al. // Transplant Proc. - 2008. - Vol. 40 (1). - P. 16-21.
Bagnati M. When and why a water soluble antioxidant becomes prooxidant during copperinduced lowdensity lipoprotein oxidation: a study using uric acid / Bagnati M., Perugini C., Cau C., et al. // Biochem J. – 1999. – Vol. 340. – P. 1431- 1452.
Bahadir O. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome / Bahadir O., Uzunlulu M., Oguz A. // Hypertens. Res. - 2007. - Vol. 30. - № 1.- P. 49-53.
Barra S. Vascular and metabolic effects of angiotensin II receptor blockers / Barra S., Vitagliano A., Cuomo V. et al. // Exp. Opin. Pharm. - 2009. - Vol. 10 (2). - P. 173-189.
Cirillo M. Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate / Cirillo M., Lanti M.P., Menotti A. et al. // Arch. Intern Med. - 2008. - Vol. 168. - P. 617-624.
Clapp B.R. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress / Clapp B.R., Hingorani A.D., Kharbanda R.K. et al. // Cardiovascо Res. - 2004. - Vol. 64. - P. 172-178.
Cuspidi C. Cardio-renal organ damage and cardiovascular outcomes in hypertension // J. Hypertens. - 2009. - Vol. 27. - P. 702-706.
DaskaLopoulou S.S. The impact of serum uric acid on cardiovascular outcomes in the LIFE stady // Kidney international. – 2004. – Vol. 66 (4). – P. 1714- 1715.
Fang J. Serum uric acid and cardiovascular mortality. The NHANES (Epidemiologic Followup Study, 1971-1992) / Fang J., Alderman M.H. //JAMA. – 2000. – Vol. 283. – P. 2404-2410.
Franse L.V. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP) / Franse L.V., Pahor M., DiBari M., et al. // J. Hypertens. – 2000. – Vol. 18. – P.1149-1154.
Goya Wannamethee S. Serum Uric Acid Is Not an Independent Risk Factor for Coronary Heart Disease // Current Hypertension Reports. – 2001. – Vol. 3. – P. 1901-1906.
Garcia Puig J. Uric acid as a cardiovascular risk factor in arterial hypertension / Garcia Puig J., Ruilope L.M. // J. Hypertens. – 1999. – Vol. 17. - P. 869-872.
Hoiggen A. The impact of serum uric acid on cardiovascular outcomes in the LIFE stady // Kidney international. - 2004. – Vol. 65. – P. 1041-1049.
Inomiya T. ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes / Inomiya T., Perkovic V., de Galan B.E. et al. // J. Amer. Soc. Nephrol. - 2009. - Vol.20. - P.1813-1821.
Johnson R.J. Reappraisal of the pathogenesis and consequences of hyperuricaemia in hypertension, cardiovascular disease, and renal disease / Johnson R.J., Kivlighn S.D., Kim Y.G. et al. // Am. J. Kidney Dis. – 1999. – Vol. 33. – P. 225-234.
Kerkalainen P. Long term association of cardiovascular risk factors with impaired insulin secretion and insulin resistance / Kerkalainen P., Sarlund H., Laakso M. // Metabolism. – 2000. – Vol. 49. – P. 1247-1254.
Mancia G. Reappraisal of European guidelines on Hypertension management: a European Society of Hypertension Task Force Document / Mancia G., Laurent S., Agabiti-Rosen et al. // J. Hypertension. - 2009. - Vol. 27. - P. 2121- 2158.
lsen M.H. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention For Endpoint reduction in hypertension study / Olsen M.H., Wachtell K., Beevers G. et al. // J. Hypertension. - 2009. - Vol. 27. - P. 567-574.
Tershakovec A.M. Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL Study / Tershakovec A.M., Keane W.F., Zhang Z. [et al.] // Diabetes Care. - 2008. - Vol. 31. - № 3. - P. 445-447.
Tan K. Effect of losartan on plasma С-reactive protein in type 2 diabetic patients with microabluminuria / Tan K., Chow W., Wong Y. // Diabetes Care. - 2002. - Vol. 25, № 7. - P. 1254-1255.
Ruilope L.M. Hyperuricemia and Renal Function / Ruilope L.M., GarciaPuig J. // Current Hypertension Reports. – 2001. – Vol. 3. – P. 197-202.
Verdecchia P. The relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The Piuma study / Verdecchia P., Schillaci G., Reboldi G.P. et al. // Hypertension. – 2000. – Vol. 36. – P. 1072-1078.
Vinuesa S.G. Insulin resistance, inflammatory biomarkes, and adipokines in patients with chronic kidney disease: effects of angiotensin II / Vinuesa S.G., Goicoechea M., Kanner J. et al. // J. Amer. Soc. Nephrol. - 2006. - Vol. 17. - P. 206- 216.
